Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association ...
A new nanomedicine strategy enhances irinotecan delivery in pancreatic tumors, reduces resistance, and boosts antitumor ...
Add Yahoo as a preferred source to see more of our stories on Google. An illustrated woman in 19th-century clothes washes ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating ...
Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in ...
SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rationally designed molecular glue ...
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...
A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...
New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying ...
In this excerpt from “We Are As Gods: A Survival God for the Age of Abundance,” authors Peter H. Diamandis and Steven Kotler ...
The MarketWatch News Department was not involved in the creation of this content.-- 4BIO Capital continues support as founding investor, having backed Ray Therapeutics since seed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results